Case Studies: Advances in Glaucoma Therapy -

Name: Case Studies: Advances in Glaucoma Therapy
Duration: 1 h 3 min 31 s
Description: NoneGRANTOR STATEMENT This Educational Activity was made possible in part by a grant from Bausch + Lomb.

Overview
NoneGRANTOR STATEMENT This Educational Activity was made possible in part by a grant from Bausch + Lomb.
Learning Objectives
Upon completion of this activity, participants will be better able to: •Explain how novel therapeutics differ in their methods of action from other topical medications. •Evaluate the safety and efficacy of latanoprostene bunod for ocular hypertension and primary open-angle glaucoma. •Describe how a healthy eye manages intraocular pressure in contrast with an unhealthy eye.
Accreditation
Accreditation Statement Evolve Medical Education LLC (Evolve) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. Credit Designation Statement Evolve designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. In cooperation with Evolve Medical Education LLC, the University of Houston College of Optometry has reviewed and endorsed this course. Evolve is an approved COPE Administrator. This course is COPE approved for 1.0 hours of CE Credit for Optometrists. COPE Course ID: 60201-GL COPE Event ID: 116630 COPE EXPIRATION DATE: December 10, 2021
Participation Method
TO OBTAIN CREDIT To obtain credit for this activity, you must read the activity in its entirety and complete the Pretest/Posttest/Activity Evaluation/Satisfaction Measures Form, which consists of a series of multiple choice questions.
Faculty and Disclosures
DISCLOSURE POLICY
It is the policy of Evolve that faculty and other individuals who are in the position to control the content of this activity disclose any real or apparent conflicts of interest relating to the topics of this educational activity. Evolve has full policies in place that will identify and mitigate all conflicts of interest prior to this educational activity.
Nathan Radcliffe, MD, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: Aerie; Alcon/Novartis; Allergan; Glaukos; Baush + Lomb; Beaver Visitec; Carl Zeiss Meditec; Ellex; Endo Optiks; Equinox; Iridex; Ivantis; Lumenis; New World Medical; Ocular Science; Omeros; Reichert; Sight Science; TearScience; Speaker: Aerie; Alcon/Novartis; Allergan; Alimera; Glaukos; Baush + Lomb; Beaver Visitec; Carl Zeiss Meditec; Equinox; Iridex; Lumenis; New World Medical; Ocular Science; Reichert; Sight Science; James Thimons, O.D., FAAO., has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Speaker: Aerie; Alcon/Novartis; Allergan; Baush + Lomb; Carl Zeiss Meditec; Diopsys; Glaukos; InFocus; PRN; Reichert; Shire; Tear Lab; Editorial Support Disclosure Susan Gallagher-Pecha, director of client services and project management, Evolve Medical Education LLC, and Erin Fletcher, MIT, Evolve Medical Education LLC, have no real or apparent conflicts of interest to report. Jaya Kumar, MD, peer reviewer has no conflict of interest to report.
Disclaimer
Off-Label Statement This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The opinions expressed in the educational activity are those of the faculty. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings. Disclaimer The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of Evolve or Bausch & Lomb.
System Requirements
- Supported Browsers (2 most recent versions):
- Google Chrome for Windows, Mac OS, iOS, and Android
  Apple Safari for Mac OS and iOS
  Mozilla Firefox for Windows, Mac OS, iOS, and Android
  Microsoft Edge for Windows
- Recommended Internet Speed: 5Mbps+
Publication Dates
Expiration Date: 12/20/2021

Case Studies: Advances in Glaucoma Therapy

Recommended

Title